AxoGen - AXGN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price objectives for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 84.2% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.

AxoGen's stock was trading at $9.98 at the start of the year. Since then, AXGN shares have decreased by 7.5% and is now trading at $9.23.
View the best growth stocks for 2023 here.

AxoGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,360,000 shares, an increase of 19.3% from the February 28th total of 1,140,000 shares. Based on an average daily trading volume, of 238,400 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.4% of the shares of the company are short sold.
View AxoGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AXGN earnings forecast.

AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analysts' expectations of $34.65 million. AxoGen had a negative trailing twelve-month return on equity of 19.05% and a negative net margin of 20.88%. During the same period in the previous year, the company posted ($0.04) EPS.

ETFs with the largest weight of AxoGen (NASDAQ:AXGN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), IQ Chaikin U.S. Small Cap ETF (CSML) and iShares U.S. Medical Devices ETF (IHI) and

AxoGen updated its FY 2023 earnings guidance on Tuesday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $158.94 million.

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (8.39%), First Light Asset Management LLC (5.61%), Bank of America Corp DE (4.30%), Point72 Asset Management L.P. (4.29%), William Blair Investment Management LLC (3.47%) and Soleus Capital Management L.P. (1.79%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXGN stock can currently be purchased for approximately $9.23.

AxoGen (NASDAQ:AXGN) has a market capitalization of $393.20 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

The company employs 428 workers across the globe.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.